Table 2.
Vimentin expression and clinicopathological parameters of breast carcinoma cases
| Variables (n) | Vimentin expression |
P | |
|---|---|---|---|
| Positive (%) 53 (75.7) | Negative (%) 17 (24.3) | ||
| Age (years) | |||
| ≤50 (32) | 25 (35.7) | 7 (10) | 0.879 |
| >50 (38) | 28 (40) | 10 (14.3) | |
| Menopausal status (n=69) | |||
| Premenopausal (16) | 12 (17.4) | 4 (5.8) | 0.770 |
| Postmenopausal (53) | 40 (58) | 13 (18.8) | |
| Histologic tumor grade | |||
| 1 (15) | 9 (12.8) | 6 (8.6) | 0.073 |
| 2 (19) | 19 (27.2) | 8 (11.5) | |
| 3 (25) | 25 (35.7) | 3 (4.3) | |
| Lymphovascular invasion | |||
| Present (44) | 36 (51.5) | 8 (11.4) | 0.207 |
| Absent (26) | 17 (24.3) | 9 (12.8) | |
| Lymph node status | |||
| Positive (56) | 44 (62.8) | 12 (17.2) | 0.443 |
| Negative (14) | 9 (12.8) | 5 (7.2) | |
| Tumor size | |||
| T1 (4) | 3 (4.3) | 1 (1.4) | 1.000 |
| T2 (44) | 33 (47.2) | 11 (15.7) | |
| T3 (15) | 11 (15.7) | 4 (5.7) | |
| T4 (7) | 6 (8.6) | 1 (1.4) | |
| Stage | |||
| 1 (2) | 1 (1.4) | 1 (1.4) | 0.398 |
| 2 (35) | 25 (35.7) | 10 (14.3) | |
| 3 (27) | 27 (38.6) | 6 (8.6) | |
| ER | |||
| Positive (23) | 13 (18.5) | 10 (58.2) | 0.020 |
| Negative (47) | 40 (57.1) | 7 (14.4) | |
| PR | |||
| Positive (22) | 13 (18.5) | 9 (12.8) | 0.058 |
| Negative (48) | 40 (57.1) | 8 (11.5) | |
| HER2/neu | |||
| Positive (42) | 30 (42.8) | 12 (17.2) | 0.460 |
| Negative (28) | 23 (32.8) | 5 (7.2) | |
| Ki67 | |||
| Positive (69) | 53 (75.7) | 16 (22.8) | 0.243 |
| Negative (1) | 0 | 1 (1.5) | |
| Subtype | |||
| TN | 18 (25.7) | 1 (1.5) | 0.028 |
| Non-TN | 35 (50) | 16 (22.8) | |
ER – Estrogen receptor; PR – Progesterone receptor; TN – Triple negative